TIPE2蛋白上调在非霍奇金淋巴瘤中的临床意义
Clinical Significance of TIPE2 Protein Upregulation in Non-Hodgkin's Lymphoma.
作者信息
Hao Chunyan, Zhang Na, Geng Minghong, Ren Qing, Li Yan, Wang Yan, Chen Youhai H, Liu Suxia
机构信息
Department of Pathology, Shandong University School of Medicine, Jinan, Shandong, P.R. China (CH, YW)
Department of Immunology, Shandong University School of Medicine, Jinan, Shandong, P.R. China (NZ, MG, YL, SL)
出版信息
J Histochem Cytochem. 2016 Sep;64(9):556-64. doi: 10.1369/0022155416662262.
Non-Hodgkin's lymphoma (NHL), which includes diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, is a refractory malignant tumor originated from the lymphatic system. TNFAIP8L2 (TIPE2 or tumor necrosis-alpha-induced protein-8 like 2) is a negative regulator for inflammation and an inhibitor for carcinogenesis. However, whether TIPE2 plays a role in lymphomagenesis is unknown. In this study, we determined TIPE2 expression in NHL by immunohistochemistry and investigated its clinicopathological significance in DLBCL. We found that TIPE2 expression was upregulated in both DLBCL and peripheral T-cell lymphoma. But the expression of TIPE2 in T lymphomas was weaker than that in DLBCL. Interestingly, among DLBCL, TIPE2 expression was significantly stronger in the germinal center B-cell (GCB) type than in the non-GCB type. These results suggest that the expression of TIPE2 protein could be a predictor of better prognosis for DLBCL.
非霍奇金淋巴瘤（NHL），包括弥漫性大B细胞淋巴瘤（DLBCL）和外周T细胞淋巴瘤，是一种起源于淋巴系统的难治性恶性肿瘤。TNFAIP8L2（TIPE2或肿瘤坏死因子-α诱导蛋白8样2）是炎症的负调节因子和致癌作用的抑制剂。然而，TIPE2是否在淋巴瘤发生中起作用尚不清楚。在本研究中，我们通过免疫组织化学确定了NHL中TIPE2的表达，并研究了其在DLBCL中的临床病理意义。我们发现TIPE2表达在DLBCL和外周T细胞淋巴瘤中均上调。但TIPE2在T细胞淋巴瘤中的表达弱于DLBCL。有趣的是，在DLBCL中，生发中心B细胞（GCB）型TIPE2的表达明显强于非GCB型。这些结果表明，TIPE2蛋白的表达可能是DLBCL预后较好的一个预测指标。
Zotero 插件